Skip to main content
. 2021 Sep 22;12:5574. doi: 10.1038/s41467-021-25904-w

Fig. 1. Correlation of ATM expression via immunohistochemistry (IHC) with benefit of addition of berzosertib to gemcitabine.

Fig. 1

a Results of ATM IHC presented by PFI strata (PFI ≤ 3 vs 3–6 months). b Figure of ATM IHC highlighting a tumor with negative ATM expression. c Figure of ATM IHC results highlighting tumor with low ATM expression. d Figure of ATM IHC results highlighting tumor with positive ATM expression. e Progression-free survival among patients with tumors with negative/low ATM expression. f Progression-free survival among patients with tumors with positive (retained) ATM expression.